Protagonist Therapeutics, Inc.
PTGX
$56.18
-$0.03-0.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.55M | 28.32M | 170.64M | 4.68M | 4.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.55M | 28.32M | 170.64M | 4.68M | 4.17M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.55M | 28.32M | 170.64M | 4.68M | 4.17M |
| SG&A Expenses | 10.55M | 11.74M | 8.95M | 10.16M | 9.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.59M | 47.63M | 43.86M | 46.13M | 42.96M |
| Operating Income | -42.04M | -19.31M | 126.78M | -41.45M | -38.79M |
| Income Before Tax | -34.60M | -11.66M | 133.66M | -33.63M | -31.29M |
| Income Tax Expenses | 172.00K | -- | 1.99M | -420.00K | -676.00K |
| Earnings from Continuing Operations | -34.77M | -11.66M | 131.67M | -33.21M | -30.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.77M | -11.66M | 131.67M | -33.21M | -30.62M |
| EBIT | -42.04M | -19.31M | 126.78M | -41.45M | -38.79M |
| EBITDA | -41.74M | -19.07M | 126.90M | -41.22M | -38.55M |
| EPS Basic | -0.55 | -0.19 | 2.11 | -0.54 | -0.50 |
| Normalized Basic EPS | -0.34 | -0.12 | 1.34 | -0.34 | -0.32 |
| EPS Diluted | -0.55 | -0.19 | 1.99 | -0.54 | -0.50 |
| Normalized Diluted EPS | -0.34 | -0.12 | 1.26 | -0.34 | -0.32 |
| Average Basic Shares Outstanding | 63.51M | 62.96M | 62.33M | 61.77M | 61.31M |
| Average Diluted Shares Outstanding | 63.51M | 62.96M | 66.41M | 61.77M | 61.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |